Journal of Eye & Cataract Surgery Open Access

  • ISSN: 2471-8300
  • Journal h-index: 5
  • Journal CiteScore: 0.38
  • Journal Impact Factor: 0.29
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Reach us +32 25889658

Plasma rich in growth factors in eye drops for the treatment of ocular surface disease

25th Edition of World Congress of OPHTHALMOLOGISTS
November 08-09, 2018 London, UK

Mari�?­a Laura Fernandez

Hospital Santa Lucia de Buenos Aires, Argentina

Scientific Tracks Abstracts: J Eye Cataract Surg

Abstract:

Plasma rich in growth factors (PRGF) is autologous 100% platelet-rich plasma as a result of an established protocol where platelets are concentrated twofold. This plasma excludes both red and white cells including leukocytes instead of being diluted as usually happen with autologous serum (AS). PRGF differentiates from other platelet-rich plasma products which have high variability in composition, protein content and platelet enrichment because its autologous origin reduces the risk of disease transmission and immunogenic reactions. In our institution different groups of patients were analyzed: VAS (Visual Analog Scale: Frequency and severity of symptoms), Dry Eye Psychometric Survey (OSDI: Ocular Surface Disease Index), BCVA (LogMAR) and Tear Breakup Time (TBUT) and Schirmer’s Test. Measurements were taken before (control) and after (PRGF) starting the treatment with PRGF. We studied the evolution of the patient throughout one year. Overall, these results demonstrate that PRGF minimizes scarring and promotes tissue regeneration in patients with moderate to severe dry eye, neurotrophic dry eye and corneal ulcers. Recent Publications 1. Anitua E, Prado R and Orive G (2015) Closing regulatory gaps: new ground rules for platelet-rich plasma. Trends Biotechnol. 33(9):492-495. 2. Riestra A C, Alonso-Herreros J M and Merayo-Lloves J (2016) [Plasma rich in platelets on the ocular surface]. Arch Soc Esp Oftalmol. 91 (10): 475-490. 3. Sanchez-Avila RM, Merayo-Lloves J, Riestra AC, et al. (2018) Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops. Int Ophthalmol. 38(3):1193-1204. 4. Ronald M Sánchez-Avila, Jesus Merayo-Lloves, Maria Laura Fernández, Luis Alberto Rodríguez-Gutiérrez, Pedro Pablo Rodríguez-Calvo, Andres Fernández- Vega Cueto, Francisco Muruzabal, Gorka Orive and Eduardo Anitua (2018) Plasma rich in growth factors eye drops to treat secondary ocular surface disorders in patients with glaucoma. International Medical Case Reports Journal 11:97-103. 5. Ronald M Sánchez-Avila, Jesus Merayo-Lloves, Maria Laura Fernández, Luis Alberto Rodríguez-Gutiérrez, Nancy Jurado, Francisco Muruzabal, Gorka Orive and Eduardo Anitua (2018) Plasma rich in growth factors for the treatment of dry eye after lasik surgery. Ophthalmic Res. 60(2):80-86.

Biography :

María Laura Fernández is an Ophthalmologist and Ocular Surface Specialist. She performs her specialty in Argentina (Hospital Santa Lucia de Buenos Aires) and in Spain (Instituto Oftalmológico Fernandez-Vega). Currently, she dedicated to evaluating the treatment with PRGF in patients with long-term ocular surface disease.

E-mail: laura.fernandez.lf@gmail.com